In collaboration with Novartis, a team of MIT researchers, including Paul I. Barton from the PSEL, has presented the first example of an 18-square-meter factory that produces the hypertension drug aliskiren in an end-to-end integrated continuous manufacturing process. Producing a continuous stream of drugs from their raw materials potentially saves time and money over traditional stop–start methods, which spread manufacture over many locations. For more on this story, click here.